

## NATTO: SHARE ISSUE

Based on the power of attorney granted at the annual general meeting of NattoPharma ASA ("NattoPharma" or "Company") on June 25, 2015, the Board of Directors of NattoPharma has in board proceedings July 21<sup>st</sup>, 2016 approved a share issue of 125 000 new shares, each with a face value of NOK 3 per share.

The share issue will be completed through issuance of new shares to strategic partners, who have over the last two years provided, and will continue to provide, valuable support for the buildup and continued development of NattoPharma. The shares will be issued to the following persons/companies;

Name	Position / Function	Granted shares	Shares prior to share issue	Shares after share issue
Katarzyna Maresz	Strategic Partner	100.000	0	100.000
Complementary Medicines Group	Strategic Partner	25.000	0	25.000

Price to be paid for each share is NOK 3 per share. The share issue is expected to be completed within August 31<sup>st</sup>, 2016.

As a result, the share capital will be increased by NOK 375 000. After completing the share issue announced 27<sup>th</sup> June of NOK 915 000, which is still in progress, and the above mentioned share issue, the Company's new share capital will be NOK 52 709 799 divided into 17 569 933 shares, each with a face value of NOK 3.

\* \* \*

For more information, please contact:

Frode Bohan, Chairman

E-mail: [frode.bohan@nattopharma.com](mailto:frode.bohan@nattopharma.com)

Kjetil Ramsøy, Chief Financial Officer

E-mail: [kjetil.ramsøy@nattopharma.com](mailto:kjetil.ramsøy@nattopharma.com)

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.